Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

Similar articles for PubMed (Select 24798718)

1.

A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients.

Maftouh M, Avan A, Funel N, Paolicchi E, Vasile E, Pacetti P, Vaccaro V, Faviana P, Campani D, Caponi S, Mambrini A, Boggi U, Cantore M, Milella M, Peters GJ, Reni M, Giovannetti E.

Pharmacogenomics. 2014 Apr;15(5):609-18. doi: 10.2217/pgs.13.225.

PMID:
24798718
2.

AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients.

Avan A, Avan A, Le Large TY, Mambrini A, Funel N, Maftouh M, Ghayour-Mobarhan M, Cantore M, Boggi U, Peters GJ, Pacetti P, Giovannetti E.

PLoS One. 2014 Sep 19;9(9):e108057. doi: 10.1371/journal.pone.0108057. eCollection 2014.

3.

Identification of novel predictive markers for the prognosis of pancreatic ductal adenocarcinoma.

Jiang B, Gu Y, Chen Y.

Cancer Invest. 2014 Jul;32(6):218-25. doi: 10.3109/07357907.2014.905586. Epub 2014 Apr 18.

PMID:
24745611
4.

SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.

Sinn M, Sinn BV, Striefler JK, Lindner JL, Stieler JM, Lohneis P, Bischoff S, Bläker H, Pelzer U, Bahra M, Dietel M, Dörken B, Oettle H, Riess H, Denkert C.

Ann Oncol. 2014 May;25(5):1025-32. doi: 10.1093/annonc/mdu084. Epub 2014 Feb 20.

5.

Induction gemcitabine plus concurrent gemcitabine and radiotherapy for locally advanced unresectable or resected pancreatic cancer.

Youl M, Hashem S, Brade A, Cummings B, Dawson LA, Gallinger S, Hedley D, Jiang H, Kim J, Krzyzanowska MK, Ringash J, Wong R, Brierley J.

Clin Oncol (R Coll Radiol). 2014 Apr;26(4):203-9. doi: 10.1016/j.clon.2014.01.003. Epub 2014 Jan 23.

PMID:
24462333
6.
7.

[Long-term survival of a patient with locally advanced unresectable pancreatic cancer treated with gemcitabine after chemoradiation therapy].

Chohno T, Aoki T, Hyuga S, Watanabe R, Matsumoto T, Takemoto H, Takachi K, Nishioka K, Uemura Y, Kobayashi K.

Gan To Kagaku Ryoho. 2013 Nov;40(12):1881-3. Japanese.

PMID:
24393953
8.

Prognostic significance of microRNA-141 expression and its tumor suppressor function in human pancreatic ductal adenocarcinoma.

Zhu ZM, Xu YF, Su QJ, Du JD, Tan XL, Tu YL, Tan JW, Jiao HB.

Mol Cell Biochem. 2014 Mar;388(1-2):39-49. doi: 10.1007/s11010-013-1897-y. Epub 2013 Nov 17.

PMID:
24242138
9.

Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.

Poplin E, Wasan H, Rolfe L, Raponi M, Ikdahl T, Bondarenko I, Davidenko I, Bondar V, Garin A, Boeck S, Ormanns S, Heinemann V, Bassi C, Evans TR, Andersson R, Hahn H, Picozzi V, Dicker A, Mann E, Voong C, Kaur P, Isaacson J, Allen A.

J Clin Oncol. 2013 Dec 10;31(35):4453-61. doi: 10.1200/JCO.2013.51.0826. Epub 2013 Nov 12.

10.

MicroRNA-101 inhibits human hepatocellular carcinoma progression through EZH2 downregulation and increased cytostatic drug sensitivity.

Xu L, Beckebaum S, Iacob S, Wu G, Kaiser GM, Radtke A, Liu C, Kabar I, Schmidt HH, Zhang X, Lu M, Cicinnati VR.

J Hepatol. 2014 Mar;60(3):590-8. doi: 10.1016/j.jhep.2013.10.028. Epub 2013 Nov 6.

PMID:
24211739
11.

Expression of microRNA-218 in human pancreatic ductal adenocarcinoma and its correlation with tumor progression and patient survival.

Zhu Z, Xu Y, Du J, Tan J, Jiao H.

J Surg Oncol. 2014 Feb;109(2):89-94. doi: 10.1002/jso.23475. Epub 2013 Oct 25.

PMID:
24166773
12.

The loss of miR-26a-mediated post-transcriptional regulation of cyclin E2 in pancreatic cancer cell proliferation and decreased patient survival.

Deng J, He M, Chen L, Chen C, Zheng J, Cai Z.

PLoS One. 2013 Oct 8;8(10):e76450. doi: 10.1371/journal.pone.0076450. eCollection 2013.

13.

EZH2-shRNA-mediated upregulation of p21waf1/cip1 and its transcriptional enhancers with concomitant downmodulation of mutant p53 in pancreatic ductal adenocarcinoma.

Batchu RB, Qazi AM, Gruzdyn OV, Semaan A, Seward SM, Chamala S, Dhulipala VB, Bouwman DL, Weaver DW, Gruber SA.

Surgery. 2013 Oct;154(4):739-46; discussion 746-7. doi: 10.1016/j.surg.2013.06.041.

PMID:
24074410
14.

miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1.

Iwagami Y, Eguchi H, Nagano H, Akita H, Hama N, Wada H, Kawamoto K, Kobayashi S, Tomokuni A, Tomimaru Y, Mori M, Doki Y.

Br J Cancer. 2013 Jul 23;109(2):502-11. doi: 10.1038/bjc.2013.320. Epub 2013 Jun 25.

15.

Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial.

Bidard FC, Huguet F, Louvet C, Mineur L, Bouché O, Chibaudel B, Artru P, Desseigne F, Bachet JB, Mathiot C, Pierga JY, Hammel P.

Ann Oncol. 2013 Aug;24(8):2057-61. doi: 10.1093/annonc/mdt176. Epub 2013 May 14.

16.

Uptake and patterns of use of gemcitabine for metastatic pancreatic cancer: a population-based study.

Oberstein PE, Hershman DL, Khanna LG, Chabot JA, Insel BJ, Neugut AI.

Cancer Invest. 2013 Jun;31(5):316-22. doi: 10.3109/07357907.2013.789904. Epub 2013 Apr 24.

PMID:
23614655
17.

Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.

Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M.

J Clin Oncol. 2013 May 1;31(13):1640-8. doi: 10.1200/JCO.2012.43.3680. Epub 2013 Apr 1.

18.

miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.

Cai B, An Y, Lv N, Chen J, Tu M, Sun J, Wu P, Wei J, Jiang K, Miao Y.

Oncol Rep. 2013 May;29(5):1769-76. doi: 10.3892/or.2013.2297. Epub 2013 Feb 21.

PMID:
23440261
19.

Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin.

Li CH, To KF, Tong JH, Xiao Z, Xia T, Lai PB, Chow SC, Zhu YX, Chan SL, Marquez VE, Chen Y.

Gastroenterology. 2013 May;144(5):1086-1097.e9. doi: 10.1053/j.gastro.2013.01.058. Epub 2013 Feb 7.

PMID:
23395645
20.

Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back.

Avan A, Pacetti P, Reni M, Milella M, Vasile E, Mambrini A, Vaccaro V, Caponi S, Cereda S, Peters GJ, Cantore M, Giovannetti E.

Int J Cancer. 2013 Aug 15;133(4):1016-22. doi: 10.1002/ijc.28078. Epub 2013 Mar 4.

PMID:
23390054
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk